Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.90 |
| ▸ | FAAH | O00519 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.64 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.64 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.64 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyceryl Monostearate SCHEMBL3047066 | 1.00 | DGKA (0.90) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL18000922 | 0.99 | DGKA (0.87) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monostearate SCHEMBL2344385 | 0.96 | DGKA (0.83) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glycerol Monolaurate SCHEMBL28322951 | 0.96 | FAAH (0.83) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL27653736 | 0.95 | DGKA (0.90) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL5158478 | 0.95 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL1237693 | 0.95 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL4398941 | 0.95 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL15604 | 0.95 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL18970879 | 0.95 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2022-05-17 | — | — | US | disclosed |
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | ANTEIS SA (CH) | 2020-03-26 | — | — | US | disclosed |
| US-10543195-B2 | Peptides for skin rejuvenation and methods of using the same | ANTEIS SA (CH) | 2020-01-28 | — | — | US | disclosed |
| EP-2970382-B1 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | ANTEIS SA (CH) | 2019-09-25 | — | — | EP | disclosed |
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | ANTEIS SA (CH) | 2016-09-22 | — | — | US | disclosed |
| US-9375398-B2 | Peptides for skin rejuvenation and methods of using the same | NEOCUTIS S.A. (CH) | 2016-06-28 | — | — | US | disclosed |
| US-9278122-B2 | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | MERZ GMBH & CO. KGAA (CH) | 2016-03-08 | — | — | US | disclosed |
| EP-2970382-A2 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | Neocutis SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20140309173-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | ANTEIS SA (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2014140890-A2 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | NEOCUTIS SA (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20130251651-A1 | Fetal Skin Cell Protein Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same | NEOGYN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8449879-B2 | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | NEOGYN, INC. (CH) | 2013-05-28 | — | — | US | disclosed |
| US-20100183723-A1 | Fetal Skin Cell Protein Compositions for the Treatment of Skin Conditions, Disorders or Diseases and Methods of Making and Using the Same | NEOCUTIS S.A. (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-1799235-A2 | FETAL SKIN CELL PROTEIN COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS, DISORDERS OR DISEASES AND METHODS OF MAKING AND USING THE SAME | Neocutis SA (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006092668-A2 | FETAL SKIN CELL PROTEIN COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS, DISORDERS OR DISEASES AND METHODS OF MAKING AND USING THE SAME | NEOCUTIS SA (CH) | 2006-09-08 | — | — | WO | disclosed |
| US-20060058238-A1 | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | NEOCUTIS S.A. (CH) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093799-A1 | Peptides for Skin Rejuvenation and Methods of Using the Same | CUTA, PLOD3, MMP13 | DGKA 1614/4885FAAH 1985/4885KDM4E 2066/4885 |
| US-11331305-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | DGKA 1614/4885FAAH 1985/4885KDM4E 2066/4885 |
| US-10543195-B2 | Peptides for skin rejuvenation and methods of using the same | CUTA, PLOD3, MMP13 | DGKA 1614/4885FAAH 1985/4885KDM4E 2066/4885 |
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | CUTA, PLOD3, MMP13 | DGKA 1614/4885FAAH 1985/4885KDM4E 2066/4885 |
| US-20140309173-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | CUTA, PLOD3, MMP13 | DGKA 1614/4885FAAH 1985/4885KDM4E 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.